SecBot SecBot
Biotech Drug Report Generated Nov 8, 2026

CB-011

CRBU·Caribou Biosciences, Inc.
BEARISH
Drug Impact Rating3/10
Trial phase
Phase 1 (discontinued)
Time to market
Not applicable. CB-011 development has been discontinued and the program terminated (Oct 2026).
Why 3/10
CB-011 has been discontinued by Caribou (announced Oct 6, 2026), so there is no upcoming PDUFA or pivotal readout. The next hard catalyst is the ASH 2026 presentation (Dec 12-15, 2026), but it is a data presentation for a terminated program, not a binary regulatory or pivotal event. The real value driver is the corporate strategic alternatives process (potential sale), which has no set date. ImpactScore is low because the drug itself no longer drives a binary outcome.
Actionable Insight BEARISH

CB-011 development has been discontinued. The next event is the ASH 2026 presentation (Dec 12-15), but it is a look-back on a terminated program. The real stock-moving catalyst is the strategic alternatives process (potential sale/merger of Caribou), which has no announced timeline. Watch for any acquisition or asset-sale announcement from the company's exploration process.

Price Chart

Loading chart...

Executive Summary

CB-011 is an allogeneic (off-the-shelf) anti-BCMA CAR-T cell therapy developed by Caribou Biosciences (CRBU) for relapsed/refractory multiple myeloma. It generated strong Phase 1 CaMMouflage trial data (92% ORR, 75% CR rate in BCMA-naive patients) and received both FDA Fast Track and RMAT designations. However, on October 6, 2026, Caribou announced it would discontinue CB-011 and its other CAR-T program (vispa-cel), cut its workforce, and explore strategic alternatives including a potential sale. The stock fell 35% after hours on the news and now trades around $0.44, down 83% from its 52-week high. ASH 2026 abstracts were accepted for December presentations, but these are look-back data for a terminated program. The drug's development is over; the remaining value lies in Caribou's strategic alternatives process.

How It Works

CB-011 is an allogeneic (off-the-shelf) CAR-T cell therapy that uses CRISPR gene editing to engineer donor immune cells to target BCMA, a protein found on multiple myeloma cancer cells. Unlike approved CAR-T therapies that must be custom-made from each patient's own cells, CB-011 is manufactured from healthy donor cells and can be given to any eligible patient without delay. The CRISPR edits are designed to prevent the donor cells from attacking the patient's body (graft-versus-host disease) and to resist rejection by the patient's immune system.

Trial Status

CB-011 was being evaluated in the Phase 1 CaMMouflage trial (dose escalation and expansion) for relapsed/refractory multiple myeloma. Positive initial data were reported in November 2025, with updated durability data at EHA 2026 (June 2026). The trial was enrolling patients at dose level 1 as of early 2023 and had identified the 450 million cell dose as the recommended dose for expansion. Caribou discontinued the program on October 6, 2026.

The Two-Sided Case

▲ Bull Case5
CB-011 generated strong Phase 1 data: 92% ORR, 75% CR rate, and 91% MRD negativity in BCMA-naive patients at the recommended dose (Nov 2025 data).
Updated EHA 2026 data showed 83% CR rate and 50% of patients in CR at 15 months, suggesting durability.
CB-011 received both FDA Fast Track designation (Apr 2023) and RMAT designation (Mar 2026), signaling regulatory interest.
Caribou held $113.8M in cash as of June 30, 2026, providing a financial cushion during the strategic alternatives process.
The strategic alternatives process could result in a sale or merger that provides value to shareholders, and the ASH 2026 presentations keep the data visible to potential acquirers.
▼ Bear Case5
CB-011 development has been permanently discontinued (Oct 2026), eliminating any future upside from the drug itself.
Caribou is exploring strategic alternatives including a potential sale, indicating the company could not secure funding to advance its pipeline.
Multiple analysts downgraded CRBU after the discontinuation announcement (HC Wainwright to Neutral, RBC to Sector Perform, Leerink to Market Perform, Brookline to Hold).
The stock trades around $0.44, down 83% over the past year from its 52-week high of $2.49, reflecting the pipeline collapse.
The allogeneic CAR-T financing environment has shifted against donor-derived approaches, favoring in vivo methods instead.

Upcoming Catalysts

  • ASH 2026 Annual Meeting (Dec 12-15, 2026): CB-011 clinical data presentation (oral/poster) for a now-discontinued program.
  • Strategic alternatives process: potential merger, acquisition, or asset sale with no announced timeline.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Caribou Biosciences, Inc. 8-K CRBU ·Originating report

Sources · 12

Hover a chip for the title
1 markets.businessinsider.com2 rttnews.com3 ad-hoc-news.de4 manilatimes.net5 nasdaq.com6 msn.com7 msn.com8 msn.com9 fiercebiotech.com10 msn.com11 markets.businessinsider.com12 markets.businessinsider.com